Home » Stocks » Akcea Therapeutics

Akcea Therapeutics, Inc. (AKCA)

Oct 13, 2020 - AKCA was delisted after being acquired by IONS
Stock Price: $18.17 USD 0.00 (0.00%)
Updated Oct 12, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 1.85B
Revenue (ttm) 336.55M
Net Income (ttm) -41.52M
Shares Out 101.62M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 12, 2020
Last Price $18.17
Previous Close $18.17
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 18.13 - 18.17
Day's Volume 0
52-Week Range 8.00 - 21.71

More Stats

Market Cap 1.85B
Enterprise Value 1.47B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 101.62M
Float 16.73M
EPS (basic) -0.36
EPS (diluted) -0.56
FCF / Share 0.94
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 5.18%
Payout Ratio n/a
Shares Short 759,276
Short Ratio 0.68
Short % of Float 4.54%
Beta 1.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 19.29
PS Ratio 5.49
PB Ratio 3.85
Revenue 336.55M
Operating Income -45.78M
Net Income -41.52M
Free Cash Flow 95.71M
Net Cash 376.34M
Net Cash / Share 3.70
Gross Margin 55.18%
Operating Margin -13.60%
Profit Margin -12.30%
FCF Margin 28.44%
ROA -5.95%
ROE -9.80%
ROIC -18.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(28.34% upside)
Current: $18.17
Target: 23.32
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth653.15%49.46%----
Gross Profit47353.1343.40---
Operating Income38.07-231-120-83.51-61.44-30.02
Net Income40.77-226-122-83.22-61.42-30.02
Shares Outstanding92.9281.3715.7528.8828.8828.88
Earnings Per Share0.29-2.87-3.08---
Operating Cash Flow224-203-36.19-55.36-44.28-29.90
Capital Expenditures-1.60-1.12-0.01-0.18-0.01-
Free Cash Flow222-204-36.20-55.54-44.29-29.90
Cash & Equivalents4642532607.8664.31-
Total Debt14.254.44----
Net Cash / Debt4492482607.8664.31-
Book Value543277168-17.7555.27-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akcea Therapeutics, Inc.
Country United States
Employees 294
CEO Damien McDevitt

Stock Information

Ticker Symbol AKCA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKCA
IPO Date July 14, 2017


Akcea Therapeutics, a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.